{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:44:42Z","timestamp":1771062282549,"version":"3.50.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,5]]},"DOI":"10.7759\/cureus.53669","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T05:13:35Z","timestamp":1707196415000},"source":"Crossref","is-referenced-by-count":1,"title":["Renal-Limited Thrombotic Microangiopathy in a Patient Who Received Gemcitabine, Ramucirumab, and Pembrolizumab: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Sumit S","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui Yi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101081","article-title":"Thrombotic microangiopathy in oncology: a review","volume":"14","author":"Val\u00e9rio P","year":"2021","unstructured":"Val\u00e9rio P, Barreto JP, Ferreira H, Chuva T, Paiva A, Costa JM. Thrombotic microangiopathy in oncology: a review. Transl Oncol. 2021, 14:101081. 10.1016\/j.tranon.2021.101081","journal-title":"Transl Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-1194-9","article-title":"Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report","volume":"20","author":"Yamada R","year":"2019","unstructured":"Yamada R, Okawa T, Matsuo K, Suzuki M, Mori N, Mori K. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report. BMC Nephrol. 2019, 20:14. 10.1186\/s12882-018-1194-9","journal-title":"BMC Nephrol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.16035","article-title":"Immune checkpoint inhibitor-associated thrombotic thrombocytopenic purpura in a patient with metastatic non-small-cell lung cancer","volume":"13","author":"De Filippis S","year":"2021","unstructured":"De Filippis S, Moore C, Ezell K, Aggarwal K, Kelkar AH. Immune checkpoint inhibitor-associated thrombotic thrombocytopenic purpura in a patient with metastatic non-small-cell lung cancer. Cureus. 2021, 13:e16035. 10.7759\/cureus.16035","journal-title":"Cureus"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2016.649","article-title":"Cancer-associated thrombotic microangiopathy","volume":"10","author":"Govind Babu K","year":"2016","unstructured":"Govind Babu K, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016, 10:649. 10.3332\/ecancer.2016.649","journal-title":"Ecancermedicalscience"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s41100-020-00278-9","article-title":"Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review","volume":"6","author":"Hayata M","year":"2020","unstructured":"Hayata M, Shimanuki M, Ko T, et al.. Pembrolizumab-associated thrombotic microangiopathy in a patient with urothelial cancer: a case report and literature review. Ren Replace Ther. 2020, 6:29. 10.1186\/s41100-020-00278-9","journal-title":"Ren Replace Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet F","year":"2019","unstructured":"Daviet F, Rouby F, Poullin P, et al.. Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort. Br J Clin Pharmacol. 2019, 85:403-12. 10.1111\/bcp.13808","journal-title":"Br J Clin Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina V","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, et al.. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008, 358:1129-36. 10.1056\/NEJMoa0707330","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.03.031","article-title":"Immune checkpoint inhibitor associated renally limited thrombotic microangiopathy: a clinical dilemma","volume":"169","author":"Badra S","year":"2022","unstructured":"Badra S, Ruchi R, Zeng X, Gordan L, Shah CV. Immune checkpoint inhibitor associated renally limited thrombotic microangiopathy: a clinical dilemma. Eur J Cancer. 2022, 169:126-30. 10.1016\/j.ejca.2022.03.031","journal-title":"Eur J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner K","year":"2012","unstructured":"Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012, 91:195-205. 10.1097\/MD.0b013e3182603598","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/226351-renal-limited-thrombotic-microangiopathy-in-a-patient-who-received-gemcitabine-ramucirumab-and-pembrolizumab-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:17:53Z","timestamp":1707509873000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/226351-renal-limited-thrombotic-microangiopathy-in-a-patient-who-received-gemcitabine-ramucirumab-and-pembrolizumab-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,5]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.53669","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,5]]}}}